NO782127L - Fremgangsmaate for fremstilling av fysiologisk aktive isoksazolo-pyridin-derivater - Google Patents

Fremgangsmaate for fremstilling av fysiologisk aktive isoksazolo-pyridin-derivater

Info

Publication number
NO782127L
NO782127L NO782127A NO782127A NO782127L NO 782127 L NO782127 L NO 782127L NO 782127 A NO782127 A NO 782127A NO 782127 A NO782127 A NO 782127A NO 782127 L NO782127 L NO 782127L
Authority
NO
Norway
Prior art keywords
isoksazolo
procedure
preparation
pyridine derivatives
physiological active
Prior art date
Application number
NO782127A
Other languages
English (en)
Other versions
NO152049C (no
NO152049B (no
Inventor
Povl Krogsgaard-Larsen
Original Assignee
Krogsgaard Larsen Povl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krogsgaard Larsen Povl filed Critical Krogsgaard Larsen Povl
Publication of NO782127L publication Critical patent/NO782127L/no
Publication of NO152049B publication Critical patent/NO152049B/no
Publication of NO152049C publication Critical patent/NO152049C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO782127A 1977-06-20 1978-06-19 Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol NO152049C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (3)

Publication Number Publication Date
NO782127L true NO782127L (no) 1978-12-21
NO152049B NO152049B (no) 1985-04-15
NO152049C NO152049C (no) 1985-07-24

Family

ID=10232513

Family Applications (3)

Application Number Title Priority Date Filing Date
NO782128A NO782128L (no) 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater
NO782127A NO152049C (no) 1977-06-20 1978-06-19 Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol
NO792839A NO792839L (no) 1977-06-20 1979-09-03 Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO782128A NO782128L (no) 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO792839A NO792839L (no) 1977-06-20 1979-09-03 Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Country Status (14)

Country Link
US (2) US4278676A (no)
EP (4) EP0027279A1 (no)
JP (2) JPS5436275A (no)
AT (1) AT368505B (no)
AU (2) AU3724478A (no)
CA (1) CA1107736A (no)
DK (2) DK270278A (no)
ES (2) ES470912A1 (no)
FI (2) FI64376C (no)
IE (1) IE47200B1 (no)
IT (2) IT7868449A0 (no)
NO (3) NO782128L (no)
NZ (1) NZ187615A (no)
ZA (2) ZA783492B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (en) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
WO2004112786A2 (en) 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
DE602005018763D1 (de) * 2004-02-18 2010-02-25 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
MX2016016136A (es) 2014-06-06 2017-07-05 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
SI3274331T1 (sl) 2015-03-24 2020-08-31 H. Lundbeck A/S Izdelava 4,5,6,7-tetrahidroizozaksolo (5,4-C)piridin-3-ol
IL305342A (en) 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3123876A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-(n-乙酰基)哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
US4278676A (en) 1981-07-14
ATA448678A (de) 1982-02-15
ES470912A1 (es) 1979-02-01
ZA783492B (en) 1979-06-27
IE47200B1 (en) 1984-01-11
DK270378A (da) 1978-12-21
EP0000338A2 (en) 1979-01-24
EP0000167A1 (en) 1979-01-10
US4301287A (en) 1981-11-17
NO152049C (no) 1985-07-24
FI64376C (fi) 1983-11-10
AT368505B (de) 1982-10-25
JPS5436275A (en) 1979-03-16
NZ187615A (en) 1981-12-15
CA1107736A (en) 1981-08-25
JPS5436290A (en) 1979-03-16
NO152049B (no) 1985-04-15
FI64376B (fi) 1983-07-29
IE781234L (en) 1978-12-20
FI781955A (fi) 1978-12-21
IT7868450A0 (it) 1978-06-20
IT1159739B (it) 1987-03-04
ES470913A1 (es) 1979-02-01
EP0000338B1 (en) 1981-11-25
ZA783493B (en) 1979-06-27
EP0027279A1 (en) 1981-04-22
IT7868449A0 (it) 1978-06-20
EP0028017A1 (en) 1981-05-06
DK270278A (da) 1978-12-21
EP0000338A3 (en) 1979-06-27
NO792839L (no) 1978-12-21
FI781954A (fi) 1978-12-21
AU521040B2 (en) 1982-03-11
AU3724478A (en) 1980-01-03
NO782128L (no) 1978-12-21
AU3729878A (en) 1980-01-03

Similar Documents

Publication Publication Date Title
NO782127L (no) Fremgangsmaate for fremstilling av fysiologisk aktive isoksazolo-pyridin-derivater
NO148148C (no) Fremgangsmaate til fremstilling av terapeutisk aktive 4-hydroksy-2-pyrrolidinonderivater
NO784211L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO784231L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive benzotiazinderivater
NO149923C (no) Analogifremgangsmaate for fremstlling av fysiologisk aktive prolinderivater
NO147243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO145657C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.
NO149962C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazolderivater
NO156611C (no) Analogifremgangsmaate for fremstilling av terapeutiske virksomme derivater av hydroksykarbonylfosfonsyre.
NO148813C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive karbostyrilderivater
NO151411C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO782756L (no) Fremgangsmaate for fremstilling av terapeutisk aktive antrakinonderivater
NO149065C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater
NO149313C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO149502C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive aminoalkoksyfenylderivater
NO149037C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
SE7803035L (sv) Forfarande for framstellning av tienopyridinderivat
NO784382L (no) Fremgangsmaate for fremstilling av tiazoldin-derivater
NO780743L (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzylpyrimidiner
NO149314C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive imidazoisokinolindioner
NO780644L (no) Fremgangsmaate til fremstilling av terapeutisk virksomme 9-hydroksyetoksymetylguanin-derivater
NO784325L (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive tetracyklononanderivater
NO794318L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater
NO152556C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antracen-biskarbonylhydrazoner